Publications by authors named "David Garcia-Azorin"
Background: The present study aimed to determine whether machine-learning (ML)-based models can predict 3-, 6, and 12-month responses to the monoclonal antibodies (mAbs) against the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRPmAbs) in patients with migraine using early predictors (up to one month) and to create an evolving prediction tool.
Methods: In this prospective cohort study data from patients with migraine who had received anti-CGRP mAbs for 12 months were collected. Demographic and monthly clinical variables were collected, including monthly headache days (MHDs), days with acute medication use, number of analgesics and Headache Impact Test-6.
Background: In this study, we aimed to evaluate the differing global access to acute and preventive medications for migraine and tension-type headache.
Methods: A custom-built questionnaire created by members of the International Headache Society Juniors Group was sent to International Headache Society members worldwide, including a list of acute and preventive treatments for migraine and tension-type headache. This list was based on evidence-based medicine guidelines.
Article Synopsis
- Migraine affects 15.2% of the global population, is a leading cause of disability, especially among women, and remains underdiagnosed and undertreated in many cases.
- The condition displays both common and individual characteristics, with a varied presentation in symptoms, frequency, and response to treatments, influenced by genetic factors.
- Education on migraine management is crucial for improving daily life for patients and reducing the number of individuals needing specialized care, allowing specialists to focus on more complex cases.
Background: Visual snow (VS) and visual snow syndrome (VSS) are becoming increasingly recognized. However, their prevalence worldwide is unknown. This study aimed to investigate lifetime prevalence and describe the clinical characteristics of VS and VSS in a representative population sample from Italy.
View Article and Find Full Text PDFArticle Synopsis
- * A committee of headache experts identified clinical questions and reviewed twenty-one national and international guidelines to develop these recommendations.
- * The guidelines outline seventeen questions related to acute migraine treatment, aiming to enhance treatment quality globally, especially in areas with limited medication access.
Infective endocarditis (IE) is a life-threating entity with three main complications: heart failure (HF), uncontrolled infection (UI) and embolic events (EEs). HF and UI are the main indications of cardiac surgery and have been studied thoroughly. On the other hand, much more uncertainty surrounds EEs, which have an abrupt and somewhat unpredictable behaviour.
View Article and Find Full Text PDFTo describe the need and effectiveness of acute and preventive medications in a series of 100 consecutive patients referred due to COVID-19-related headaches. Patients were aged 48.0 (standard deviation (SD): 12.
View Article and Find Full Text PDFBackground: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting.
Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics.
Article Synopsis
- Anti-CGRP monoclonal antibodies are effective treatments for preventing migraines, but patients show varied responses, influenced by specific clinical factors.
- A study involving over 5,800 patients identified key predictors of treatment response at 6 months, including older age, unilateral pain, absence of depression, fewer monthly migraine days, and lower disability levels.
- The findings highlight that higher migraine frequency and greater baseline disability negatively impact treatment effectiveness, which can inform future patient management and reimbursement policies.
Background And Purpose: Influenza is a common cause of acute respiratory infection, with headache being one of the symptoms included in the European Commission case definition. The prevalence of headache as a symptom of influenza remains unknown. We aimed to describe the incidence and prevalence of headache in patients with influenza.
View Article and Find Full Text PDFIntroduction: Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine.
Methods: Observational, multicenter, prospective cohort study.
Purpose: Migraine is the comorbidity most frequently associated with visual snow syndrome (VSS), but the prevalence of VSS in patients with migraine (PWM) has not been studied. Our objective was to evaluate the frequency of VSS in PWM and to analyze if symptoms of VSS happened in a permanent or episodic manner (eVSS) in this population.
Methods: We conducted a multicenter observational cross-sectional study.
Background: The burden of migraine goes beyond the pain and associated symptoms. We aimed to describe the impact of migraine in healthcare resource utilization (HCRU), work productivity, and mood disorders, as well as its economic cost.
Methods: Case-control study nested in a cross-sectional analysis of patient-reported data collected between 30/12/2019 and 20/04/2020 as part of the National Health and Wellness Survey, from respondents located in Spain.
Background And Purpose: Anti-calcitonin gene-related peptide (CGRP) therapies are recent preventive therapies approved for both episodic and chronic migraine. One of the measures of effectiveness is the withdrawal of other preventive treatments. The objective of this study is to quantify the impact of anti-CGRP drugs in concomitant preventive treatment in patients with migraine.
View Article and Find Full Text PDFCurrent definitions of migraine that are based mainly on clinical characteristics do not account for other patient's features such as those related to an impaired quality of life, due to loss of social life and productivity, and the differences related to the geographical distribution of the disease and cultural misconceptions which tend to underestimate migraine as a psychosocial rather than neurobiological disorder.Global differences definition, care access, and health equity for headache disorders, especially migraine are reported in this paper from a collaborative group of the editorial board members of the Journal of Headache and Pain. Other components that affect patients with migraine, in addition to the impact promoted by the migraine symptoms such as stigma and social determinants, are also reported.
View Article and Find Full Text PDFArticle Synopsis
- This systematic review and meta-analysis aimed to assess the prevalence of thirteen neurological issues in COVID-19 patients during and after the acute phase of the illness, with follow-ups at 3, 6, 9, and 12 months.
- The study analyzed data from 126 eligible studies with over 1.5 million COVID-19 subjects, focusing on neurological symptoms like fatigue, cognitive impairment, and anosmia, among others.
- Results showed that during the acute phase, the most common neurological symptoms were anosmia/hyposmia, fatigue, and headaches, with some symptoms like fatigue and cognitive impairment remaining significant even at the 3-month follow-up.
Background And Purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption.
View Article and Find Full Text PDF